Scottsdale, Arizona (PRWEB) June 24, 2012
QualityStocks would like to highlight Cellceutix, a publicly traded bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Their flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism.
In the company’s news last week,
Cellceutix said the U.S. Food and Drug Administration (FDA) has reviewed the company’s Investigational New Drug (IND) application for its novel anti-cancer compound Kevetrin™ and has approved the company’s advancement to phase I clinical trial.
The phase 1 clinical trial for Kevetrin will take place at Harvard Cancer Center’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.
The company also announced that both the Institutional Review Board and the Scientific Review Committee have approved the protocol for the clinical trial.
Cellceutix said it will provide details on the commencement of the clinical trials to shareholders next week.
Cellceutix is focused on the discovery of small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases. In addition to its flagship compound Kevetrin, the company owns the rights to seven other drug compounds, including KM-133 in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.